| Compatibility and stability of telavancin and vancomycin in heparin or sodium citrate lock solutions. | |
| | |
MedLine Citation:
|
PMID: 22855107 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
PURPOSE: The compatibility and stability of telavancin and vancomycin in heparin or sodium citrate lock solutions were evaluated. METHODS: Telavancin and vancomycin hydrochloride injection powder lyophilized for solution were reconstituted with 0.9% sodium chloride injection at room temperature according to the manufacturer's instructions and then further diluted with (1) commercially available heparin sodium to reach a final heparin concentration of 2500 units/mL or (2) sodium citrate solution 2.2% or 4% to achieve final telavancin and vancomycin concentrations of 2 and 5 mg/mL. Physical stability, chemical compatibility, and biological anticoagulant stability were analyzed for each antibiotic-anticoagulant combination immediately after preparation and at 24, 48, and 72 hours. Changes in coagulation were measured at each time point and compared using two-way analysis of variance. RESULTS: Both telavancin and vancomycin retained at least 90% of the initial concentration after incubation at 37 °C over 72 hours. The biological stability of vancomycin 2 mg/mL and telavancin 2 mg/mL did not significantly alter prothrombin time when compared with that of 0.9% sodium chloride injection. However, telavancin 5 mg/mL and vancomycin 5 mg/mL significantly increased the activated partial thromboplastin time at 72 hours compared with the control solution. Visual precipitation only occurred with vancomycin-containing solutions; however, this dissipated after 10 minutes. CONCLUSION: Telavancin 2 and 5 mg/mL was physically compatible in combination with heparin 2500 units/mL and with sodium citrate 2.2% and 4% over 72 hours. Vancomycin 2 and 5 mg/mL initially precipitated in the sodium citrate 2.2% formulation, but no precipitation was noted after 10 minutes of incubation at 37 °C. Telavancin and vancomycin 2 and 5 mg/mL retained over 90% of the initial concentration after incubation at 37 °C over 72 hours. |
| | |
Authors:
|
Kerry L LaPlante; Suzanne Woodmansee; Leonard A Mermel |
Related Documents
:
|
2295107 - Analgesia and serum concentrations of extradural, subdural and intraperitoneal fentanyl... 10626717 - Onset of spinal block is more rapid with isobaric than hyperbaric bupivacaine. 11300387 - Total knee replacement: a comparison of ropivacaine and bupivacaine in combined femoral... 7793647 - Clinical effects and maternal and fetal plasma concentrations of epidural ropivacaine v... 2496967 - Further characterization of the neurofunctional effects of the calcium ionophore a23187. 19169687 - A phase i escalating single-dose and weekly fixed-dose study of cetuximab pharmacokinet... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists Volume: 69 ISSN: 1535-2900 ISO Abbreviation: Am J Health Syst Pharm Publication Date: 2012 Aug |
Date Detail:
|
Created Date: 2012-08-02 Completed Date: 2012-12-04 Revised Date: 2013-04-04 |
Medline Journal Info:
|
Nlm Unique ID: 9503023 Medline TA: Am J Health Syst Pharm Country: United States |
Other Details:
|
Languages: eng Pagination: 1405-9 Citation Subset: IM |
Affiliation:
|
Department of Pharmacy Practice, University of Rhode Island, 144 Fogarty Hall, Kingston, RI 02881, USA. kerrytedesco@uri.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aminoglycosides
/
administration & dosage,
chemistry* Anti-Bacterial Agents / administration & dosage, chemistry Anticoagulants / administration & dosage, chemistry Catheter-Related Infections / prevention & control Catheterization, Central Venous / adverse effects Citrates / administration & dosage, chemistry* Drug Combinations Drug Incompatibility Drug Stability Heparin / administration & dosage, chemistry* Humans Infusions, Intravenous Isotonic Solutions Thrombosis / prevention & control Time Factors Vancomycin / administration & dosage, chemistry* |
| Chemical | |
Reg. No./Substance:
|
0/Aminoglycosides; 0/Anti-Bacterial Agents; 0/Anticoagulants; 0/Citrates; 0/Drug Combinations; 0/Isotonic Solutions; 1404-90-6/Vancomycin; 1Q73Q2JULR/sodium citrate; 9005-49-6/Heparin; XK134822Z0/telavancin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Method to determine allocation of clinical pharmacist resources.
Next Document: Survey of learning opportunities in academia for pharmacy residents.